Norn Groups’s Talent Bridge: Come to America and make the world live longer

We sponsor the best talent from around the world with grants and networking, to come to America and pursue projects that advance longevity.

Sep 12 • Norn Group, Martin Borch Jensen, and Effie Klimi

9

2

3

July 2026

Sisyphus, MD.

How humanity’s pursuit of healthy years must evolve from treating individual diseases to building the infrastructure needed to target aging itself.

Jul 24 • Norn Group and Effie Klimi

14

1

4

May 2026

Ask not what AI can do for longevity. Ask what the longevity field can do for AI.

AI needs task-shaped datasets. By default it will accelerate progress at the biological layers we already measure well. Solutions for longevity live at…

May 15 • Martin Borch Jensen

38

14

23

March 2026

An indication selection resource for longevity companies

We're sharing a spreadsheet with key data on 47 diseases that aging drugs could potentially treat, to help fresh startups and academic scientists pick…

Mar 25 • Norn Group

14

1

7

Advancing Longevity Trials: Lessons from mTOR-Targeting Interventions

What two decades of trials can teach us about translating rapamycin to human aging.

Mar 7 • Norn Group and Nicolas Di Leo

14

5

January 2026

Field Notes: JPM 2026

Healthcare bursting at the seams, and a national longevity strategy roundtable.

Jan 21

8

1

4

Do we have a useful aging clock?

13 years after the first 'aging clock' was published we're still measuring mouse lifespan and unable to run human aging trials. What's missing?

Jan 2 • Martin Borch Jensen

14

2

6

December 2025

The Slop Map

A Field Guide to Longevity Content

Dec 17, 2025 • Martin Borch Jensen and Effie Klimi

13

4

2

Norn Notes 20251201

Nucleus Genomics is a longevity company?

Dec 1, 2025

1

1

November 2025

How to Design a Clinical Trial for Aging

Current incentives push companies away from true aging drugs and toward single-indication development. This essay suggests an ‘aging’ Phase III trial…

Nov 26, 2025 • Martin Borch Jensen, Márton Mészáros, Brennan Overhoff, and Norn Group

22

5

8

October 2025

Why there are no trillion-dollar biotechs.

Nvidia is worth more than every pharmaceutical company. Some say biotech CEOs should see this as a challenge. But if they try for the big T, markets…

Oct 15, 2025 • Martin Borch Jensen

32

4

4

September 2025

Avoiding the Gerontocene

America’s choices on policy and research priorities today could determine whether the coming decade brings us yet closer to a shrinking fraction of…

Sep 21, 2025 • Martin Borch Jensen, Sean Simonini, and Eshan Mehra

7

3